On this page
What each program costs in Nevada
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Nevada Public Employees' Benefits Program (PEBP) cover GLP-1s for weight loss?
Nevada's PEBP provides weight-loss medications through its voluntary, opt-in Obesity Care Management Program, alongside medically supervised weight loss and nutritional counseling, per its plan year 2026 benefit guide.
Getting a GLP-1 online in Nevada
The Nevada State Board of Pharmacy told compounding pharmacies to stop compounding, distributing and dispensing copies of tirzepatide and semaglutide injections once FDA removed both from its shortage list, with May 22, 2025 the last date for outsourcing facilities on semaglutide.
Nevada State Board of Pharmacy
The Board's notice to compounding pharmacies requires them to follow FDA's declaratory orders on tirzepatide and semaglutide and stop compounding these injections.
“This letter serves as notice that your pharmacy must comply with both Declaratory Orders and cease the compounding, distributing, and dispensing of compounded tirzepatide injection and semaglutide injection products as of the effective dates below.”
https://www.bop.nv.gov/siteassets/content/resources/all/Notice_to_Compound_Pharm_re_Tirzepatide_semaglutide_FINAL.pdf · read Oct 29, 2026
Nevada State Board of Pharmacy
For outsourcing (503B) facilities, the semaglutide cutoff was May 22, 2025.
“After May 22, 2025, 503B pharmacies may no longer compound, distribute, or dispense compounded semaglutide injection products.”
https://www.bop.nv.gov/siteassets/content/resources/all/Notice_to_Compound_Pharm_re_Tirzepatide_semaglutide_FINAL.pdf · read Oct 29, 2026
Does Nevada Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Nevada Medicaid's manual says it will not reimburse agents used for weight management, so it does not cover Wegovy or Zepbound for weight loss. Read from state documents Nov 6, 2026.
What Nevada Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Nevada Health Authority, Nevada Medicaid.
WegovyNo
Prior authorization for heart risk in people with established heart disease and no diabetes, or for the liver condition MASH.
“Nevada Medicaid will not reimburse for the following pharmaceuticals:”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“1. Agents used for weight management.”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“Medication is being prescribed for risk reduction of major adverse cardiovascular events”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
ZepboundNo
Prior authorization for moderate to severe sleep apnea in adults with obesity and no diabetes.
“Nevada Medicaid will not reimburse for the following pharmaceuticals:”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“1. Agents used for weight management.”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“Medication is being prescribed for moderate to severe obstructive sleep apnea (OSA) in adults with obesity”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
OzempicNo
Incretin mimetic criteria require type 2 diabetes uses and prior authorization. The manual does not name this brand.
“Nevada Medicaid will not reimburse for the following pharmaceuticals:”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“1. Agents used for weight management.”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“Medication is not being prescribed for weight loss in absence of T2DM indication”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
MounjaroNo
Incretin mimetic criteria require type 2 diabetes uses and prior authorization. The manual does not name this brand.
“Nevada Medicaid will not reimburse for the following pharmaceuticals:”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“1. Agents used for weight management.”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
“Medication is not being prescribed for weight loss in absence of T2DM indication”
Nevada Medicaid, Medicaid Services Manual Chapter 1200 · Effective Aug 31, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Nevada Health Authority, Nevada Medicaid documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
1,240 prescriptions
Ozempic and Mounjaro, 2025
61,578 prescriptions
Neighbours covering weight loss
0 of 5
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Nevada Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Nevada Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Nevada Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Nevada Medicaid pay for?
70,791 GLP-1 prescriptions in 2025, 30th of the 50 states and DC, with $77.1 million reimbursed before rebates. Counting the share other payers covered, $81.7 million.
Prescriptions, 2025
70,791
30th of 51
Medicaid paid
$77.1M
28th of 51, before rebates
Per prescription
$1,090
$1,051 nationally
Weight-loss brands
1.8%
35th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Nevada is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 1.8% of Nevada Medicaid's GLP-1 prescriptions in 2025 (1,240). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Nevada Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 42,402 | 60% | $45.6 million | $1,076 |
| Mounjaro | 19,176 | 27% | $22.4 million | $1,166 |
| Trulicity | 4,482 | 6.3% | $5.3 million | $1,190 |
| Liraglutide (generic) | 1,792 | 2.5% | $506,478 | $283 |
| Rybelsus | 1,671 | 2.4% | $1.9 million | $1,133 |
| Wegovyapproved for weight management | 876 | 1.2% | $1.1 million | $1,208 |
| Zepboundapproved for weight management | 364 | 0.5% | $346,976 | $953 |
| Bydureon | 28 | 0.0% | $20,629 | $737 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Nevada?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 3 in Nevada. The register does not say which, if any, supplies a program on this page.
- AnazaoHealth Corporation, Las Vegas. Registered since Sep 23, 2014; last FDA inspection Aug 8, 2025.
- Bespoke Pharmaceutical, LLC, Las Vegas. Registered since Mar 7, 2026; not yet inspected by FDA.
- Rapha Pharmaceuticals, lnc., Las Vegas. Registered since Dec 23, 2024; not yet inspected by FDA.
On Medicare in Nevada?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Nevada and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 5 states next to Nevada covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Nevada's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Nevada | Not covered | 19 | $39/mo |
| Arizona | Not covered in part | 19 | $39/moWellmedr |
| California | Not covered | 17 | $39/moWellmedr |
| Idaho | Not covered | 19 | $39/moWellmedr |
| Oregon | Not covered | 19 | $39/moWellmedr |
| Utah | Not confirmed | 19 | $39/moWellmedr |






















